FOR IMMEDIATE RELEASE

CONTACT:

Investor Relations	Debra Berliner
Tiens Biotech Group (USA), Inc.	G. S. Schwartz & Co.
Tel: +86-22-8213-7335	Tel: 212-725-4500
Fax: +86-22-8213-7914	Fax: 212-725-9188
Email: investor@tiens-bio.com	Email: dberliner@schwartz.com
http://www.tiens-bio.com

TIENS BIOTECH GROUP (USA) REPORTS 2010 RESULTS

TIANJIN, CHINA – March 31, 2011 –Tiens Biotech Group (USA), Inc. (the “Company” or “Tiens”, NYSE AMEX: TBV), a company dedicated to the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements, today announced financial results for the year ended December 31, 2010.

For 2010, revenue was $41.3 million, compared to $62.0 million for 2009.

Net income for 2010 was $4.8 million, or $0.07 per share, compared to $23.8 million, or $0.33 per share for 2009.

Results for 2010 mainly reflect a decrease in international sales. For 2010, international revenue was $16.4 million, compared to $34.7 million for 2009. In 2008, China’s Administration of Quality Supervision, Inspection and Quarantine carried out a national campaign against unsafe food and substandard products, which brought on a general slow-down and backlog of export clearances for Chinese food products. Upon the lifting of the regulations, overseas affiliated companies began to purchase more products, thereby increasing sales for 2009.

In addition, Tiens’ Indonesia affiliated company has not purchased from the Company during the year of 2010, given they purchased more products in 2009 after the 2008 product scarcity for the reason noted above. In addition, local Original Equipment Manufacturers in Indonesia have been producing healthcare products with the Company’s semi-finished goods, which have a profit margin that is much lower than the profit margin of finished goods.

Tiens’ affiliated companies in many regions have made certain adjustments to their marketing programs and reorganizations at their branch and higher levels, which are expected to boost sales performance over the long-run, but negatively affect short-term sales.

Other Highlights

Cost of sales were $15.0 million in 2010 compared to $20.2 million in 2009, a decrease of 25.6%. This decrease was primarily due to the corresponding decrease in sales. Cost of sales decreased at a lower rate than revenue, primarily due to fixed costs, which do not increase or decrease in line with sales.

Gross profit decreased by 37.0% to $26.3 million in 2010, compared to $41.8 million in 2009. The gross profit margin for 2010 was 63.7% compared to 67.5% in 2009.

Selling, general and administrative expenses increased by 22.0% to $19.5 million in 2010, compared to $16.0 million in 2009. The increase was primarily due to increases in allowance for bad debt ($1.9 million), salaries expenses ($0.7 million) and research & development expenses ($0.6 million).

As of December 31, 2010, Tiens had $128.0 million of retained earnings and total shareholders' equity of $285.5 million.

In addition, Tiens reported that on March 11, 2011, Tianjin Tianshi Biological Engineering Co., Ltd. (Tianshi Engineering) was awarded a direct selling license in Tianjin.

Jinyuan Li, Chairman, President and CEO of Tiens, said, “We remain confident that domestic sales will return to, and potentially exceed, previous levels, as distributors begin to replenish their stock of our products. In addition, we maintain this same positive sentiment regarding international sales, which we expect will benefit from the removal of export restrictions and gradual economic improvement. We are steadfast in our commitment to building greater market share in China, expanding our international customer base, and further implementing our strategic plans for long-term domestic and international growth.”

About Tiens Biotech Group (USA), Inc. www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (NYSE AMEX: TBV) conducts its business operations from Tianjin, People’s Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 45 countries. Since its establishment, Tiens has developed and produced 37 nutrition supplements, which include wellness products and dietary supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens’ products in China through chain stores, domestic affiliated companies, and its 87 branches. Outside of China, Tiens sells its products to affiliated companies in 45 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company’s direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) whether the Company continues to experience delays in the export clearance of its products; and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov.

-Tables Follow-

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE YEARS ENDED DECEMBER 31, 2010 and 2009

	2010			2009
REVENUE - RELATED PARTIES	$	41,021,135		$	60,032,968
REVENUE - THIRD PARTIES		323,585			1,943,101

COST OF SALES - RELATED PARTIES		14,850,739			18,754,680
COST OF SALES - THIRD PARTIES		158,638			1,412,812

GROSS PROFIT		26,335,343			41,808,577

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		19,530,501			16,009,382

INCOME FROM OPERATIONS		6,804,842			25,799,195

Interest expense		(230,905	)		(186,543	)
Interest income		18,362			301,709
Other expense		35,965			(176,757	)
OTHER EXPENSE, NET		(176,578	)		(61,591	)

INCOME BEFORE INCOME TAXES		6,628,264			25,737,604

INCOME TAXES		1,469,548			930,703

NET INCOME		5,158,716			24,806,901

LESS: Net income attributable to the noncontrolling interest		(323,101	)		(965,557	)

NET INCOME ATTRIBUTABLE TO THE COMPANY		4,835,615			23,841,344

OTHER COMPREHENSIVE INCOME:
Foreign currency translation adjustment		5,131,503			441,140
Loss from the realization of foreign currency sale		-			(6,030,079	)

COMPREHENSIVE INCOME ATTRIBUTABLE
TO THE COMPANY		9,967,118			18,252,405

COMPREHENSIVE INCOME ATTRIBUTABLE
TO THE NONCONTROLLING INTEREST		664,854			993,504

COMPREHENSIVE INCOME	$	10,631,972		$	19,245,909

EARNINGS PER SHARE,
BASIC AND DILUTED	$	0.07		$	0.33

WEIGHTED AVERAGE NUMBER OF SHARES,
BASIC AND DILUTED		71,333,586			71,333,586

The accompanying notes are an integral part of this statement.

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2010 AND DECEMBER 31, 2009

	December 31,		December 31,
	2010		2009
A S S E T S

CURRENT ASSETS:
Cash	$	10,155,522	$	1,848,328
Accounts receivable, trade - related parties, net of
allowance for doubtful accounts of $3,869,617 and $1,419,178
as of December 31, 2010 and December 31, 2009 , respectively		10,012,861		15,379,312
Inventories		5,703,349		5,328,052
Other receivables		1,045,952		995,657
Other receivables - related parties		17,376,522		44,561,626
Employee advances		170,842		115,673
Prepaid expenses, net		415,208		658,193
Prepaid taxes		3,646,140		407,534
Total current assets		48,526,396		69,294,375

PROPERTY, PLANT AND EQUIPMENT, net		72,037,542		10,124,483

OTHER ASSETS:
Construction in progress		128,715,283		125,572,621
Construction deposits		12,490,855		1,405,997
Intangible assets, net		12,987,000		12,864,295
Other assets		10,721,040		11,847,937
Total other assets		164,914,178		151,690,850

Total assets	$	285,478,116	$	231,109,708

L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y
CURRENT LIABILITIES:
Accounts payable	$	14,120,791	$	5,012,157
Advances from customers - related parties		8,688,877		4,426,751
Wages and benefits payable		1,613,782		1,484,852
Short-term debt		3,024,800		-
Income taxes payable		490,782		-
Contractor deposits		209,376		183,395
Contractor payables		28,134,711		18,513,216
Other payables		1,113,416		1,151,551
Other payables - related parties		1,417,516		3,326,110
Total current liabilities		58,814,051		34,098,032

NON-CURRENT LIABILITIES
Long term debt		18,451,280		-
Deferred income		11,473,853		11,236,501
Total non current liabilities		29,925,133		11,236,501
Total liabilities		88,739,184		45,334,533

Commitments and Contingencies

EQUITY:
Shareholders' equity of the Company:
Common stock, $0.001 par value, 250,000,000 shares authorized,
71,333,586 issued and outstanding, respectively		71,334		71,334
Paid-in-capital		18,349,908		18,042,189
Statutory reserves		16,465,144		13,217,217
Retained earnings		127,957,951		126,370,263
Accumulated other comprehensive income		23,393,626		18,262,123
Total shareholders' equity of the Company		186,237,963		175,963,126
Noncontrolling interest		10,500,969		9,812,049
Total equity		196,738,932		185,775,175
Total liabilities and equity	$	285,478,116	$	231,109,708

The accompanying notes are an integral part of this statement.

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2010 AND 2009

	2010			2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	5,158,716		$	24,806,901
Adjustments to reconcile net income to cash
provided by (used in) operating activities:
Deferred income		(142,070	)		-
Provision for doubtful accounts		2,349,703			406,795
Increase (decrease) provision for obsolete inventory		(237,632	)		309,343
Depreciation		2,036,280			2,173,251
Amortization		338,019			381,742
Interest expense		167,586			4,761
(Gain) loss on sale of assets		(63,773	)		47,054
Loss on assets written off		40,982			5,876
Rental expense borne by a related party		330,708			326,774
(Increase) decrease in assets:
Accounts receivable, trade - related parties		3,411,877			8,308,993
Other receivables		(16,036	)		(184,540	)
Other receivables - related parties		9,936,038			1,668,812
Inventories		93,315			2,761,335
Employee advances		(50,112	)		(38,359	)
Prepaid expense		258,945			(419,419	)
Increase (decrease) in liabilities:
Accounts payable		8,742,972			(1,249,152	)
Advances from customers - related parties		21,603,664			1,178,463
Wages and benefits payable		76,914			(43,279	)
Other taxes payable		(2,674,295	)		968,294
Other payables		(74,068	)		(650,296	)
Other payables - related parties		9,069,853			3,107,699
Net cash provided by operating activities		60,357,586			43,871,048

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash outflow arising from disposal of a subsidiary		-			(23,975,473	)
Collections from loans to local government		-			105,229
Construction deposits		(11,248,302	)		(2,664,741	)
Contractor deposits		19,306			19,734
Addition to construction in progress		(54,487,459	)		(42,734,161	)
Equipment deposits		(6,102,039	)		(11,782,984	)
Proceeds from sales of properties		73,650			29,131
Purchase of equipment and automobiles		(1,441,906	)		(2,009,536	)
Net cash used in investing activities		(73,186,750	)		(83,012,801	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Loan from (repayment to) related parties		-			(3,946,860	)
Proceed from short term debt		2,958,800			-
Proceeds from long term debt		18,048,680			-
Net cash provided by (used in) financing activities		21,007,480			(3,946,860	)

EFFECT OF EXCHANGE RATE CHANGES ON CASH		128,878			82,430

INCREASE (DECREASE) IN CASH		8,307,194			(43,006,183	)

CASH, beginning of period		1,848,328			44,854,511


CASH, end of period	$	10,155,522		$	1,848,328

Supplemental disclosures of cash flow information
Cash paid during the period for:
Interest	$	217,154		$	105,817
Income taxes	$	1,489,417		$	3,287,531

The accompanying notes are an integral part of this statement.

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

REVENUE BY REGION

	Twelve months ended
	December 31,

	2010		2009		Change

China	$	24,894,472	$	27,241,333		- 8.6	%
International	$	16,450,248	$	34,734,736		-52.6	%
Total	$	41,344,720	$	61,976,069		-33.3	%

TIENS BIOTECH GROUP USA INC 8-K